Last reviewed · How we verify
Tysabri
Tysabri is a Small molecule drug developed by University of Chicago. It is currently FDA-approved for Crohn's disease, Multiple sclerosis. Also known as: Natalizumab, BG00002, natalizumab, Natalizumab BG00002.
At a glance
| Generic name | Tysabri |
|---|---|
| Also known as | Natalizumab, BG00002, natalizumab, Natalizumab BG00002 |
| Sponsor | University of Chicago |
| Target | Integrin alpha-4/beta-1, Integrin alpha-4/beta-7 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Crohn's disease
- Multiple sclerosis
Common side effects
- Headache
- Fatigue
- Arthralgia
- Urinary tract infection
- Lower respiratory tract infection
- Gastroenteritis
- Vaginitis
- Depression
- Pain in extremity
- Abdominal discomfort
- Diarrhea NOS
- Rash
Key clinical trials
- Evaluation of Early Changes Visible to the Diffusion MRI in Response to Two Years of Treatment With Tysabri in Patients With Multiple Sclerosis (PHASE4)
- Study of the Mechanisms of Action of Cladribine in Multiple Sclerosis (NA)
- Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS) (PHASE2)
- Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) (PHASE3)
- Implication of 5-HT7 Receptor in Inflammatory Mechanisms in Multiple Sclerosis
- Cladribine Tablets After Treatment With Natalizumab (CLADRINA) (PHASE4)
- A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis (PHASE3)
- A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tysabri CI brief — competitive landscape report
- Tysabri updates RSS · CI watch RSS
- University of Chicago portfolio CI
Frequently asked questions about Tysabri
What is Tysabri?
Tysabri is a Small molecule drug developed by University of Chicago, indicated for Crohn's disease, Multiple sclerosis.
What is Tysabri used for?
Tysabri is indicated for Crohn's disease, Multiple sclerosis.
Who makes Tysabri?
Tysabri is developed and marketed by University of Chicago (see full University of Chicago pipeline at /company/university-of-chicago).
Is Tysabri also known as anything else?
Tysabri is also known as Natalizumab, BG00002, natalizumab, Natalizumab BG00002.
What development phase is Tysabri in?
Tysabri is FDA-approved (marketed).
What are the side effects of Tysabri?
Common side effects of Tysabri include Headache, Fatigue, Arthralgia, Urinary tract infection, Lower respiratory tract infection, Gastroenteritis.
What does Tysabri target?
Tysabri targets Integrin alpha-4/beta-1, Integrin alpha-4/beta-7.
Related
- Target: All drugs targeting Integrin alpha-4/beta-1, Integrin alpha-4/beta-7
- Manufacturer: University of Chicago — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Crohn's disease
- Indication: Drugs for Multiple sclerosis
- Also known as: Natalizumab, BG00002, natalizumab, Natalizumab BG00002